Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-05-17 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2021年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of the 2021 Annual General Meeting (AGM) of 福安药业（集团）股份有限公司. It details the legality and compliance of the AGM's notice, agenda, voting procedures, and resolutions passed, including approval of the 2021 annual reports, audit reports, financial statements, profit distribution, and other corporate governance matters. The document does not contain the actual annual report or financial statements but rather confirms the validity and legality of the AGM and its resolutions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the official voting results and legitimacy of the shareholder meeting decisions. The document length is over 5,000 characters and contains detailed voting results, supporting this classification with high confidence.
2022-05-17 Chinese
关于子公司收到左氧氟沙星注射液药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (715 characters) about a subsidiary receiving a drug registration certificate from the national drug regulatory authority. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official announcement regarding regulatory approval of a product, not a financial report or management disclosure. The document is an announcement of a regulatory event related to the company, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories.
2022-05-09 Chinese
关于收到注射用还原型谷胱甘肽药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about its subsidiary receiving approval from the national drug regulatory authority for a supplementary drug application. It details the approval of changes related to drug specifications and manufacturing processes. The document is short (946 characters) and serves as an official notification of regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it is the announcement itself. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-04-28 Chinese
独立董事关于2021年度对外担保事项的独立意见补充公告
Regulatory Filings Classification · 95% confidence The document is a supplementary announcement by independent directors regarding the company's external guarantees for the fiscal year 2021. It provides an independent opinion on the company's guarantee activities and compliance with relevant laws and regulations. The document is relatively short (836 characters) and serves as an announcement or supplement to a previously disclosed opinion rather than a full report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-04-26 Chinese
2021年度非经营性资金占用及其他关联资金往来情况专项审核报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年度非经营性资金占用及其他关联资金往来情况专项审核报告" which translates to a "2021 Special Audit Report on Non-operating Fund Occupation and Other Related Party Fund Transactions". It is issued by an accounting firm and references an audit conducted under Chinese CPA auditing standards. The document includes detailed financial data related to non-operating fund occupation and related party transactions for the fiscal year 2021. It is a standalone audit report focusing on specific audit procedures and findings related to non-operating funds and related party transactions, not a full annual report or interim report. The document is about 3825 characters, which is relatively short but contains substantive audit content and financial data, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2021
2022-04-25 Chinese
2021年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2021 年度财务决算报告' which translates to '2021 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2021, including income statement, balance sheet, cash flow statement, and financial ratios. The report mentions audited financial statements with an unqualified audit opinion. The length is about 4880 characters, which is sufficient to contain substantive financial data rather than just an announcement. The content includes comprehensive financial performance and position for the full fiscal year 2021, consistent with an Annual Report (10-K) type document. There is no indication that this is merely an announcement or a certification letter, so it should not be classified as RPA or RNS. Therefore, the document is best classified as an Annual Report (10-K). FY 2021
2022-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.